Just been thinking about the current pharma landscape and honestly, Wall Street's obsession with Eli Lilly right now is pretty wild. Everyone's chasing GLP-1 exposure because of the weight loss drug craze, and yeah, Mounjaro and Zepbound are genuinely strong products. But here's the thing - the market's pricing in perfection at this point.

Lilly's sitting at a P/E of 44 with a dividend yield of just 0.6%. That's thin if you're actually looking for income. And with those two drugs making up 56% of the company's revenue, there's some real concentration risk that Wall Street seems to be glossing over. The 2025 growth numbers are impressive - 99% and 175% respectively - but that also means a lot depends on maintaining that momentum.

If you want dividend exposure in pharma without the GLP-1 hype bubble, Merck's worth a closer look. They're operating in different spaces - oncology, infectious disease, cardiometabolic treatments. Not as trendy right now, but these are massive therapeutic areas that matter.

Here's where Merck gets interesting: P/E of 16 versus Lilly's 44, and the yield is 2.8% compared to that miserable 0.6%. That's a real income difference. Keytruda's got some patent challenges coming, sure, but they've got international protection extending into the early 2030s, plus a new delivery method that could push things further. The payout ratio sits around 50%, which is solid and sustainable.

Merck's also got three decades of steady dividend growth backing it up. Not every single year, but the trend is clear. You're not buying into a company priced for perfection here - you're buying into a solid, mature pharma business with actual yield.

Lilly isn't broken as a business, but the valuation's gotten stretched. If you're the type who actually wants dividend income from your pharma holdings, Merck's probably going to serve you better right now. Sometimes the less flashy play ends up being the smarter one.